SCHEMBL973008

SCHEMBL973008

CC(O)N1CCN(N)CC1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL64047 0.85
SCHEMBL11771179 0.85
SCHEMBL483206 0.85 ALDH1A1 (0.46) ALDH1A1LMNA
SCHEMBL2316270 0.78 ALDH1A1 (0.33) ALDH1A1LMNA
SCHEMBL19069125 0.77 CHRNA7 (0.42) ALDH1A1LMNA
SCHEMBL883791 0.77 CHRNA7 (0.37) ALDH1A1LMNA
SCHEMBL179844 0.74
SCHEMBL6266438 0.74 MC4R (0.41) ALDH1A1LMNA
SCHEMBL7128647 0.74 ALDH1A1 (0.35) ALDH1A1LMNA
SCHEMBL21150247 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115605529-B Photochromic polydiorganosiloxane vinyl cross-linking agent 爱尔康公司 2024-03-26 CN disclosed
CN-116888193-A Polysiloxane vinyl cross-linking agent with high refractive index 爱尔康公司 2023-10-13 CN disclosed
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-03-07 US disclosed
EP-2295436-A1 2-Phenyl-subsitituted Imidazotriazinones as Phosphodiesterase V inhibitors Bayer Schering Pharma AG (DE) 2011-03-16 EP disclosed
US-20110009367-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-01-13 US disclosed
EP-1666504-B1 Use of maleimide derivatives in water compatible energy curable compositions SUN CHEMICAL CORP (US) 2010-09-08 EP disclosed
US-7704999-B2 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-27 US disclosed
US-7696206-B2 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-04-13 US disclosed
US-20100016323-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-01-21 US disclosed
US-20080113972-A1 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors BAYER AKTIENGESELLSCHAFT (DE) 2008-05-15 US disclosed
CN-1291201-A Water compatible energy curable compositions containing maleimide derivatives SUN CHEMICAL CORP (US) 2001-04-11 CN disclosed
CN-1278822-A 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors BAYER AG (DE) 2001-01-03 CN disclosed
EP-1049695-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER AG (DE) 2000-11-08 EP disclosed
WO-1999024433-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 1999-05-20 WO disclosed
EP-0878482-A1 An active energy ray curable composition comprised of a maleimide derivative and a method for curing the said curable composition DAINIPPON INK AND CHEMICALS, INC. (JP) 1998-11-18 EP disclosed
CN-1189821-A Substituted oximes, hydrazones and olefins as neurokinin antagonists SCHERING CORP (US) 1998-08-05 CN disclosed
US-5756765-A BACTERICIDES AND ANTIBIOTICS CHONG KUN DANG CORP. (KR) 1998-05-26 US disclosed
US-5641770-A THIENAMYCINS ANTIBIOTICS CHONG KUN DANG CORP. (KR) 1997-06-24 US disclosed
EP-0674640-A1 2-(2-SUBSTITUTED PYRROLIDIN-4-YL)THIO-CARBAPENEM DERIVATIVES CHONG KUN DANG CORP (KR) 1995-10-04 EP disclosed
WO-1994014811-A1 2-(2-SUBSTITUTED PYRROLIDIN-4-YL)THIO-CARBAPENEM DERIVATIVES CHONG KUN DANG CORP. (KR) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016323-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS PDE3A, PDE2A, PDE3B ALDH1A1 323/4885LMNA 2491/4885
US-20080113972-A1 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors PDE3B, PDE3A, PDE2A ALDH1A1 670/4885LMNA 2421/4885
US-20110009367-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE2A ALDH1A1 670/4885LMNA 2421/4885
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE2A ALDH1A1 670/4885LMNA 2421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.